<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114304">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902667</url>
  </required_header>
  <id_info>
    <org_study_id>13/EE/0186 CCR3992</org_study_id>
    <nct_id>NCT01902667</nct_id>
  </id_info>
  <brief_title>Preoperative Imaging in Retroperitoneal Sarcoma</brief_title>
  <acronym>PIRS</acronym>
  <official_title>Preoperative Imaging in Retroperitoneal Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational study in which patients with untreated retroperitoneal
      sarcoma will have Magnetic Resonance Imaging (MRI) prior to surgery. In addition, patients
      who will be undergoing pre-operative radiotherapy will have an additional MRI scan at two
      weeks post radiotherapy. For both groups, the magnetic resonance images will be correlated
      with tumour pathology.

      The study hypothesis is that Magnetic Resonance Imaging will provide a more accurate
      assessment of tumour volume and local staging than CT and will identify areas of altered
      oxygenation, cellularity and perfusion which change in response to radiotherapy before
      tumour shrinkage occurs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prediction, by MRI, of early response to radiotherapy prior to tumour shrinkage</measure>
    <time_frame>2-4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in volume, maximum axial diameter, ADC, F, D, D*, T2, R2* and enhancing fraction from baseline to post radiotherapy will be presented. A paired T-test (or Wilcoxon Signed Rank Test) may be used to test the difference between baseline and post radiotherapy. Differences in these values will be presented for responders and non-responders, which will be tested by independent T-test. Response will be determined by tumour size, enhancing fraction and histopathological evidence of response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the reproducibility of multi-parametric MRI measurements within tumour regions of interest in patients with retroperitoneal sarcoma.</measure>
    <time_frame>1-7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reproducibility of the parameter ADC-Apparent Diffusion Coefficient (also F, D, D*, T2 and R2* values)between the two scans at baseline (within 7 days of each other)will be assessed using the Bland Altman method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of imaging features with histopathological assessment of tumour size, local staging, cellularity, necrosis and viable tumour.</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between the ADC (and D) and %ki 67 uptake, % necrosis, %fat content, % of viable tumour, % hyalinization/fibrosis, % dedifferentiated component, cellularity and stroma morphology will be assessed using the Pearson's correlation coefficient or the Spearman's (whichever is appropriate).</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Curative intent surgery alone</arm_group_label>
    <description>Patients with retroperitoneal sarcoma randomised into surgery alone arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-operative radiotherapy plus surgery</arm_group_label>
    <description>Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <arm_group_label>Curative intent surgery alone</arm_group_label>
    <arm_group_label>Pre-operative radiotherapy plus surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with retroperitoneal sarcoma randomised for preoperative radiotherapy plus
        surgery versus surgery alone.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with retroperitoneal sarcomas planned for surgical resection +/-
             preoperative radiotherapy.

        Exclusion Criteria:

          -  MRI incompatible metal implants

          -  claustrophobia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christina Messiou, Dr</last_name>
    <phone>0208 661 3216</phone>
    <email>christina.messiou@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine May, BSc</last_name>
    <phone>0208 642 6011</phone>
    <phone_ext>4109</phone_ext>
    <email>katherine.may@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Messiou, Dr</last_name>
      <phone>0208 661 3216</phone>
      <email>christina.messiou@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Katherine May, BSc</last_name>
      <phone>0208 6613340</phone>
      <email>katherine.may@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Cancer Research, United Kingdom</investigator_affiliation>
    <investigator_full_name>NdeSouza</investigator_full_name>
    <investigator_title>Professor of Translational Imaging</investigator_title>
  </responsible_party>
  <keyword>Retroperitoneal Sarcoma</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
